Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyBlue Cross Blue Shield NC denosumab Coverage Updat…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - North CarolinaPolicy N/A

    Denosumab (Prolia, Xgeva) and Denosumab Biosimilars coverage

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, product list, dosing/HCPCS guidance, and prior authorization requirements for denosumab (Prolia/Xgeva) and specified biosimilars for Blue Cross Blue Shield North Carolina members.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyDenosumab (Prolia, Xgeva) and Denosumab Biosimilars coverage
    Policy CodePolicy N/A
    Change TypeAdded biosimilarscoding and step-therapy revisions
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document trial and failure of designated preferred biosimilars (or submit FDA MedWatch and supporting documentation if claiming serious adverse events) before requesting non-preferred denosumab products.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Added new to market Prolia (denosumab) biosimilars Bildyos (denosumab-nxxp) and Bosaya (denosumab-kyqq) to policy for the same FDA approved indications as Prolia and with the same coverage criteria requirements.

    Designated Bosaya, Conexxence, and Ospomyv as non-preferred denosumab products requiring trial and failure of preferred biosimilars Jubbonti AND Stoboclo, or documented serious adverse events with both preferred products plus FDA MedWatch submission.

    Added new Xgeva biosimilars Aukelso (denosumab-kyqq) and Bilprevda (denosumab-nxxp) and set non-preferred status for several Xgeva biosimilars requiring trial and failure of preferred products Osenvelt AND Wyost or documented serious adverse events with MedWatch submission.

    Added requirement of trial and failure of an IV bisphosphonate for multiple myeloma and solid tumor with bone metastases indications for Xgeva and its biosimilars; added new oncologic indications with IV bisphosphonate trial requirements where specified.

    Adjusted HCPCS coding: added Q5157/Q5158/Q5159 for specific biosimilars effective 10/1/2025 and removed unspecified miscellaneous codes (C9399, J3490, J3590, J9999) as of 9/30/2025 for those products.

    Changed policy name to include denosumab biosimilars and adjusted maximum units for oncology indications to 9999 to indicate unlimited units.

    14Named restricted products listed
    365Duration of approval (most indications)
    Q5157–Q5159New HCPCS codes added
    9999Max units (oncology)

    Medical Necessity and Coverage Criteria

    Osteoporosis indications (Prolia and selected biosimilars)

    Covered when ALL of the following are met

    Product and age: Request is for Prolia (denosumab) or one of the specified Prolia biosimilars (Bildyos [denosumab-nxxp], Bosaya [denosumab-kyqq], Conexxence [denosumab-bnht], Jubbonti [denosumab-bbdz], Ospomyv [denosumab-dssb], or Stoboclo [denosumab-bmwo]); AND the patient is 18 years of age or older.

    [[chunk 3]]

    Diagnosis: Patient has a diagnosis of osteoporosis.

    [[chunk 3]]

    Population: Patient is a male over 50 years OR a postmenopausal female.

    [[chunk 3]]

    High fracture risk: Patient is at high risk for fracture, defined by history of osteoporotic fracture OR multiple risk factors for fracture.

    [[chunk 3],[chunk 5]]

    Prior bisphosphonate: Patient has previously been treated with a bisphosphonate and experienced therapeutic failure/inadequate response OR is unable to receive a bisphosphonate due to contraindication or hypersensitivity.

    [[chunk 3],[chunk 4]]

    Breast cancer on aromatase inhibitor (when applicable): If the patient has breast cancer and is receiving aromatase inhibitor therapy, one of the prior bisphosphonate conditions (therapeutic failure OR contraindication/hypersensitivity) must be met.

    [[chunk 3]]

    Nonmetastatic prostate cancer on ADT (when applicable): If the patient has nonmetastatic prostate cancer and is receiving androgen deprivation therapy, one of the prior bisphosphonate conditions (therapeutic failure OR contraindication/hypersensitivity) must be met.

    [[chunk 3]]

    Glucocorticoid-induced osteoporosis specific: For glucocorticoid-induced osteoporosis: patient is at high fracture risk; initiating or continuing systemic glucocorticoids at >= 7.5 mg prednisone (or equivalent) daily and expected to remain on therapy for at least 6 months; AND prior bisphosphonate trial with therapeutic failure OR contraindication/hypersensitivity applies.>= 7.5 mg prednisone daily and expected >= 6 months

    [[chunk 5]]

    Step requirement for certain products: If the request is for Prolia, Bildyos, Bosaya, Conexxence, Ospomyv, or a non-preferred denosumab product, ONE of the step criteria must be met (trial and inadequate response to preferred biosimilars, intolerance/contraindication to preferred biosimilars, or documented serious adverse event to preferred biosimilars with FDA MedWatch submission).

    [[chunk 5]]

    Osteoporosis in patients receiving cancer therapy

    Covered when ALL of the following are met

    Diagnosis and therapy: Patient has a diagnosis of breast cancer AND is currently receiving aromatase inhibitor therapy (e.g., anastrozole, letrozole, exemestane).

    [[chunk 3]]

    Prior bisphosphonate: Patient has previously been treated with a bisphosphonate and experienced therapeutic failure/inadequate response OR is unable to receive a bisphosphonate due to contraindication/hypersensitivity.

    [[chunk 3]]

    Oncology indications (Xgeva and selected biosimilars)

    Covered when ALL of the following are met

    Oncology indications (eligible list): Indications include: multiple myeloma for prevention of skeletal-related events; solid tumors with documented bone metastases for prevention of skeletal-related events; giant cell tumor of bone in adults or skeletally mature adolescents (>=12) when unresectable, recurrent, or when surgery would cause severe morbidity; hypercalcemia of malignancy refractory to bisphosphonates; breast cancer with bone metastases; castration-resistant prostate cancer with bone metastases; systemic mastocytosis (as specified).

    [[chunks 6,7,8]]

    Prior IV bisphosphonate: For multiple myeloma, solid tumor with bone metastases, and specified breast cancer indications: patient had prior treatment with an intravenous bisphosphonate and experienced therapeutic failure/inadequate response OR has intolerance/FDA-labeled contraindication/hypersensitivity to IV bisphosphonate therapy.

    [[chunks 6,7,8]]

    No combination therapy: Patient will NOT be using the requested agent in combination with a bisphosphonate, another form of denosumab (e.g., Prolia or Xgeva), romosozumab-aqqg, or a parathyroid hormone analog for osteoporosis (e.g., abaloparatide, teriparatide).

    Step requirement for non-preferred denosumab products

    Covered when ONE of the following is met

    Preferred biosimilar failure: Patient tried and had an inadequate response to ALL designated preferred denosumab biosimilars for the product group (two specified products) with medical record documentation (e.g., Jubbonti AND Stoboclo for certain Prolia biosimilars; Osenvelt AND Wyost for certain Xgeva biosimilars).

    [[chunk 9],[chunk 5]]

    Intolerance/contraindication to preferred biosimilars: Patient has intolerance, FDA-labeled contraindication, or hypersensitivity to both preferred biosimilars that is not expected to occur with the requested agent (medical record documentation required).

    [[chunk 9],[chunk 5]]

    Serious adverse event to preferred biosimilars: Patient has a documented serious adverse event requiring medical intervention to both preferred biosimilars that is not anticipated with the requested agent; prescriber must complete and submit an FDA MedWatch Adverse Event Reporting Form (documentation required).

    [[chunk 9],[chunk 5]]

    Non-preferred biosimilar approval criteria

    Coverage for denosumab biosimilars is aligned with the same FDA-approved indications as the reference products, with additional step therapy and trial/failure requirements for non-preferred biosimilars.

    Non-preferred biosimilar coverage requirements: Coverage requires prior trial and failure of two designated preferred biosimilar products (for example, Jubbonti AND Stoboclo for certain Prolia biosimilars; Osenvelt AND Wyost for certain Xgeva biosimilars), OR documented serious adverse events requiring medical intervention from both preferred products that are not anticipated with the requested non-preferred product plus submission of an FDA MedWatch Adverse Event Reporting Form. Medical record documentation of trials, failures, intolerances, or adverse events is required.

    Applies where product is designated non-preferred per policy.

    Xgeva biosimilars oncology criteria

    Oncology-specific additional requirements for Xgeva and its biosimilars

    Oncology IV bisphosphonate requirement: For multiple myeloma and solid tumor with bone metastases indications (and for specified breast cancer with bone metastases indications), coverage of Xgeva or Xgeva biosimilars requires prior trial and failure of an intravenous bisphosphonate before approval of Xgeva or its biosimilars. Documentation of prior IV bisphosphonate trial, therapeutic failure, or intolerance/contraindication is required.

    [[chunk 20]]

    Requests for denosumab products are not eligible for coverage if the member will be receiving the requested denosumab agent in combination with another bone-active product for the same osteoporosis indication. Specifically, coverage is contingent on the absence of concurrent therapy with a bisphosphonate, another form of denosumab (for example, Prolia or Xgeva), romosozumab‑aqqg, or a parathyroid hormone analog (e.g., abaloparatide, teriparatide). Documentation in the medical record must confirm no concurrent use of these agents at the time of request.

    Denosumab must not be prescribed or approved in combination with other denosumab products or other bone active agents. Coverage is expressly prohibited when the requested product would be used together with a bisphosphonate, another form of denosumab (such as Prolia or Xgeva), romosozumab‑aqqg, or a parathyroid hormone analog for osteoporosis.

    Requests that do not meet the indication‑specific medical necessity criteria are considered not medically necessary and will be denied. This includes failure to document required prior therapy (for example, prior oral or IV bisphosphonate or required trials of preferred denosumab biosimilars), lack of documentation of a contraindication or intolerance to a required comparator, or missing evidence to support the requested indication. Denials may also occur when required documentation of serious adverse events and submission of an FDA MedWatch form (where applicable) are not provided.

    Use of HCPCS codes that were deleted or terminated (for example, C9399, J3490, J3590, J9999) after their termination dates may cause claims to be non‑adjudicable or administratively unacceptable until corrected. Providers must bill with the current product‑specific HCPCS codes (such as the Q51xx codes added effective 10/1/2025) per the policy to avoid processing denials.

    HCPCS and ICD-10 Coding Guidance

    Referenced HCPCS / Billing CodesHCPCS
    J0897Denosumab injection (HCPCS referenced for Prolia/Xgeva and some biosimilars)
    Q5136HCPCS referenced for Wyost (denosumab-bbdz) / Jubbonti (denosumab-bbdz)
    Q5157HCPCS referenced for Stoboclo / Osenvelt (denosumab-bmwo)
    Q5158HCPCS referenced for Conexxence / Bomyntra (denosumab-bnht)
    Q5159HCPCS referenced for Ospomyv / Xbryk (denosumab-dssb)
    C9399Miscellaneous HCPCS code cited for some biosimilars (Aukelso, Bilprevda, and others)
    J3490Unclassified drugs HCPCS cited
    J3590Unclassified biologics HCPCS cited
    J9999Not otherwise classified HCPCS cited
    HCPCS/Coding referencedHCPCS
    C9399Unclassified biologics (previously listed; deletions noted effective 9/30/2025)
    J3490Unclassified drugs (previously listed; deletions noted effective 9/30/2025)
    J3590Unclassified biologics (previously listed; deletions noted effective 9/30/2025)
    J9999Not otherwise classified (previously listed; deletions noted effective 9/30/2025)
    Q5157Denosumab-bmwo (Stoboclo/Osenvelt) (1 unit per 1 mg) (added 10/1/2025)
    Q5158Denosumab-bnht (Bomyntra/Conexxence) (1 unit per 1 mg) (added 10/1/2025)
    Q5159Denosumab-dssb (Ospomyv/Xbryk) (1 unit per 1 mg) (added 10/1/2025)
    Q5136HCPCS code associated with Jubbonti/Wyost (referenced)
    Referenced ICD-10 CodesICD-10
    C00.0-C49.9Range of oncology ICD-10 codes listed as applicable
    C50.011-C79.9Oncology diagnosis code ranges listed
    M81.0Osteoporosis code specifically listed
    M81.8Other osteoporosis codes
    T50.905Toxic effect / drug code referenced
    Z51.11Encounter for antineoplastic radiation
    Z51.12Encounter for antineoplastic chemotherapy
    Z79.811Long term (current) use of bisphosphonates
    Z87.311Personal history of (healed) pathological fracture
    HCPCS/Coding referencedHCPCS
    C9399Unclassified biologics (previously listed; deletions noted effective 9/30/2025)
    J3490Unclassified drugs (previously listed; deletions noted effective 9/30/2025)
    J3590Unclassified biologics (previously listed; deletions noted effective 9/30/2025)
    J9999Not otherwise classified (previously listed; deletions noted effective 9/30/2025)
    Q5157Denosumab-bmwo (Stoboclo/Osenvelt) (1 unit per 1 mg) (added 10/1/2025)
    Q5158Denosumab-bnht (Bomyntra/Conexxence) (1 unit per 1 mg) (added 10/1/2025)
    Q5159Denosumab-dssb (Ospomyv/Xbryk) (1 unit per 1 mg) (added 10/1/2025)
    Q5136HCPCS code associated with Jubbonti/Wyost (referenced)
    ICD-10 codes referencedICD-10
    C00.0-C49.9Neoplasms range - example codes listed
    C50.011-C79.9Breast cancer and metastatic neoplasm codes (examples)
    M81.0Age-related osteoporosis without current pathological fracture
    M81.8Other osteoporosis without current pathological fracture
    T50.905Poisoning by unspecified drugs, medicaments and biological substances (example listed)
    Z51.11Encounter for antineoplastic chemotherapy
    Z51.12Encounter for antineoplastic immunotherapy
    Z79.811Long term (current) use of denosumab
    Z87.311Personal history of (other) pathologic fracture
    Glucocorticoid daily dose threshold — osteoporosis criteria
    Glucocorticoid threshold>= 7.5 mg prednisone daily and expected to remain on therapy for at least 6 months
    Applies toGlucocorticoid‑induced osteoporosis criteria for Prolia and specified biosimilars
    Documentation requiredMedical record must document daily prednisone-equivalent dose and expected duration of >=6 months
    Maximum units for oncology indications
    Maximum units (oncology indications)9999 (indicates unlimited units)
    Purpose

    Prior Authorization, Documentation, and Step Therapy Requirements

    Prior Authorization

    Prior Authorization and Coding Requirements

    Prior authorization required for denosumab products. Requests must include the correct, product-specific HCPCS/administration codes and meet the policy's indication‑specific medical necessity criteria, dosing, and maximum quantity limits. For oncology uses, include the pertinent cancer ICD‑10 diagnosis code on the claim when applicable.

    • Prior authorization must be obtained before administration for all restricted denosumab products listed in policy.
    • Include product‑specific HCPCS codes (see dosing/coding table) on prior authorization and claim submissions.
    • For oncology indications, submit the cancer ICD‑10 diagnosis code in addition to denosumab administration codes.
    Step Therapy

    Biosimilar Step Therapy Requirement

    Step therapy applies to non‑preferred denosumab products. When a non‑preferred denosumab is requested, the prescriber must document trial and inadequate response to the designated preferred denosumab biosimilars (examples provided in the policy).

    Clinical Background

    Denosumab is a monoclonal antibody that inhibits RANK ligand and thereby reduces osteoclast‑mediated bone resorption. It is indicated across multiple settings including treatment of osteoporosis (e.g., Prolia dosing of 60 mg subcutaneously every 6 months for eligible adults) and prevention of skeletal‑related events in oncology (e.g., Xgeva dosing of 120 mg subcutaneously every 4 weeks for indicated malignancy‑related uses). The policy aligns coverage of denosumab and specified biosimilars with FDA‑approved indications and dosing, while applying indication‑specific prior authorization, step therapy, and quantity limits.

    Key Definitions and Diagnostic Coding Notes

    High risk for fracture — definition
    DefinitionHigh risk for fracture = history of osteoporotic fracture OR multiple risk factors for fracture
    Population examplesPostmenopausal women and men at high risk for fracture (FDA‑labeled uses)
    Role in criteriaRequired element in osteoporosis coverage criteria to establish medical necessity
    Oncology diagnosis coding — cancer ICD-10 requirement
    RequirementFor oncology uses include the pertinent cancer ICD‑10 diagnosis code alongside denosumab administration codes when certain codes are used (examples listed in policy)
    Example ICD‑10 rangesC00.0-C49.9, C50.011-C79.9 (oncology code ranges listed in policy)
    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyDenosumab (Prolia, Xgeva) and Denosumab Biosimilars coverage
    Policy CodePolicy N/A
    Change TypeAdded biosimilarscoding and step-therapy revisions
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document trial and failure of designated preferred biosimilars (or submit FDA MedWatch and supporting documentation if claiming serious adverse events) before requesting non-preferred denosumab products.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaHCPCS and ICD-10 Coding GuidancePrior Authorization, Documentation, and Step Therapy RequirementsClinical BackgroundKey Definitions and Diagnostic Coding Notes

    [[chunk 9]]

    Quantity limits and duration: Requested quantity does not exceed maximum units allowed for the duration of approval; duration of approval for these oncology indications is 365 days unless otherwise specified and quantity limits per indication apply.

    [[chunk 9]]

    Clarifies maximum quantity allowance for oncology dosing durations
    Policy noteChanged to 9999 to indicate unlimited units for clarity
    • Non‑preferred denosumab requests require documented trials of the specified preferred biosimilars and evidence of inadequate response or intolerance.
    • Examples of required prior trials: Jubbonti (denosumab‑bbdz) AND Stoboclo (denosumab‑bmwo) for certain Prolia non‑preferred agents; Osenvelt AND Wyost for certain Xgeva non‑preferred agents (see policy criteria).
    Documentation Required

    Documentation Required for Non‑Preferred Product Approval

    When approval for a non‑preferred denosumab product is requested due to intolerance, contraindication, or a serious adverse event to preferred biosimilars, medical record documentation is required. For serious adverse events, the prescriber must submit supporting documentation including the completed FDA MedWatch Adverse Event Reporting Form.

    • Document prior trials and the nature of inadequate response or intolerance in the medical record.
    • For documented serious adverse events related to preferred biosimilars, include medical records describing the event, interventions, and the submitted FDA MedWatch form.
    • If claiming intolerance or contraindication, include clinical rationale why the preferred biosimilars are not appropriate and why the requested agent is expected to be tolerated.
    Denial Risk

    Denial Risk and Billing/Coding Rules

    Failure to document required step therapy trials, or submission using deleted/terminated HCPCS miscellaneous codes after their termination dates, may result in claim non‑adjudication or denial. Requests not meeting the medical necessity criteria (including age, diagnosis, prior therapy, or contraindication documentation) may be denied.

    • Do not use terminated HCPCS miscellaneous codes (C9399, J3490, J3590, J9999) after their termination date (9/30/2025) — update to the current Q‑codes (e.g., Q5157, Q5158, Q5159, Q5136 as applicable) effective 10/01/2025.
    • Provide complete medical record evidence of prior therapy trials and failures; absence of this documentation may lead to denial.
    • Requests missing required age, diagnosis, or contraindication documentation are at high risk for denial.
    Specific codes that trigger requirementM81.0, M81.8, T50.905, Z79.811, Z87.311 require accompanying cancer diagnosis code for oncology use